Leveraging omics for cancer discoveries
As an interdisciplinary computational biologist, my research focuses on developing and implementing integrative computational approaches to omics data sets to reveal novel insight into cancer development and therapy resistance.
I have collaborated extensively with basic science and clinical investigators in the areas of bulk and single-cell genomics and epigenomics, including several multi-omics correlative studies utilizing clinical specimens from NIH-funded clinical trials.
Implementation and analysis of immunogenomics and single-cell approaches to understand the evolving tumor immune microenvironment (TIME) in cancer development and immunotherapeutic resistanceSee the science
Leveraging multi-omics approaches to study determinants of lineage plasticity in cancerRead the research
Roswell Park – University of Chicago Ovarian Cancer SPORE
- The mission: Reducing the morbidity and mortality of ovarian cancer through innovative translational research
- The award: Career Enhancement Program Pilot Grant
- The scientist: Mark Long, PhD
- The research: Application of translational multi-omics approaches to derive the features of exceptional response to a novel combination immunotherapy regimen in chemotherapy refractory ovarian cancer
Cancer Moonshot: Create an adult immunotherapy network
The Immuno-Oncology Translational Network (IOTN) is a consortium to accelerate translation of basic discoveries to clinical applications to improve immunotherapy outcomes for both “hot” and “cold” cancers – and to prevent cancers before they occur.
As a member of the Data Management and Resource-Sharing Center (DMRC), Dr. Long collaborates with scientists across the country to conduct highly effective and innovative translational studies to address the significantly unmet clinical needs related to immuno-oncology.